Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
56.95 USD 1.58 ( 2.85%)
Last update at 2026-11-18T21:00:00Z
VOLUME
2113518
Market Cap
1862.61M

Momentum Score

…

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
55.00
Low
57.59
High
52 Week Price Range
9.22
Low
39.99
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Axogen develops and commercializes surgical solutions for peripheral nerve repair, notably regenerative nerve grafts and protective soft-tissue products for traumatic and surgical nerve injuries. Long-term growth may be supported by wider clinical adoption, expanded indications, international expansion and rising procedure volumes from an aging population, and the company appears positioned as a focused specialist with surgeon training and product differentiation.
Key risks include reliance on a narrow procedure set with variable reimbursement, competition from autografts and alternative technologies, and execution and financial constraints that could impede growth.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
55.37
Dividend Yield
-
Revenue TTM
225.21M
Revenue Per Share
4.89
Gross Profit TTM
167.35M
Debt / Equity
0.15
ROE
-13.49%
Net Debt
-16.31M
ROCE
-4.04%
Diluted EPS TTM
-0.34

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -15.70M -9.96M -21.72M -28.95M -26.98M
Net income -15.70M -9.96M -21.72M -27.34M -28.06M
Selling general administrative 44.58M 39.04M 38.41M 36.76M 32.34M
Selling and marketing expenses 97.74M 78.46M 77.58M 80.23M 73.33M
Gross profit 167.35M 141.98M 121.87M 114.44M 104.43M
Reconciled depreciation 8.51M 7.84M 4.87M 4.85M 4.74M
Ebit -8.00M -1.76M -18.88M -29.71M -25.42M
Ebitda 0.19M 6.08M -13.33M -25.08M -20.95M
Depreciation and amortization 8.19M 7.84M 5.55M 4.62M 4.46M
Non operating income net other - - - 1.38M -0.21M
Operating income -7.85M -3.29M -21.46M -29.71M -25.42M
Other operating expenses 233.06M 190.62M 180.47M 168.29M 152.77M
Interest expense 7.70M 8.21M 2.83M 0.62M 1.36M
Net interest income -7.70M -8.21M -0.95M -0.62M -1.36M
Income tax expense - - 5.39M -1.61M 1.08M
Total revenue 225.21M 187.34M 159.01M 138.58M 127.36M
Total operating expenses 175.20M 145.26M 143.33M 144.14M 129.84M
Cost of revenue 57.85M 45.36M 37.14M 24.15M 22.93M
Total other income expense net -7.85M -6.68M -0.25M 0.76M -1.57M
Net income from continuing ops -15.70M -9.96M -23.24M -28.95M -26.98M
Net income applicable to common shares - - - -28.95M -26.98M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 221.69M 203.73M 196.83M 195.39M 208.02M
Intangible assets 6.75M 5.58M 4.53M 3.65M 2.86M
Other current assets 16.33M 8.45M 2.81M 1.94M 1.86M
Total liab 92.84M 99.82M 101.16M 94.39M 95.47M
Total stockholder equity 128.85M 103.91M 95.67M 101.00M 112.55M
Deferred long term liab - - - 4.52M 5.56M
Other current liab 21.18M 20.63M 17.11M 13.48M 16.54M
Common stock 0.47M 0.44M 0.43M 0.42M 0.42M
Capital stock 0.47M 0.44M 0.43M 0.42M 0.42M
Retained earnings -306.96M -291.26M -281.30M -259.58M -230.63M
Cash 35.55M 27.55M 37.03M 15.28M 32.76M
Total current liabilities 23.56M 30.61M 30.43M 23.75M 24.29M
Net debt -16.31M 41.13M 32.27M 52.14M 34.70M
Short term debt 2.37M 1.97M 1.55M 1.31M 1.83M
Short long term debt total 19.24M 68.69M 69.29M 67.43M 67.45M
Other stockholder equity 435.34M 394.73M 376.53M 360.15M 342.76M
Property plant equipment - - - 93.66M 78.12M
Total current assets 120.42M 99.22M 88.00M 98.08M 127.05M
Net tangible assets - - - 97.35M 109.69M
Short term investments 5.98M 5.93M 0.00M 33.51M 51.33M
Net receivables 26.17M 24.11M 25.15M 22.19M 18.16M
Long term debt 48.39M 47.50M 46.60M 66.12M 65.62M
Inventory 42.37M 33.18M 23.02M 18.91M 16.69M
Accounts payable 2.89M 8.01M 11.77M 8.96M 5.92M
Accumulated other comprehensive income - - 0.00M - -
Common stock total equity - - - 0.42M 0.42M
Retained earnings total equity - - - -259.58M -230.63M
Non currrent assets other - - - 93.66M 0.04M
Non current assets total 101.27M 104.51M 108.82M 97.31M 80.97M
Capital lease obligations 19.24M 21.19M 22.69M 21.71M 22.63M
Long term debt total - - - 66.12M 65.62M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.28M -10.30M 18.32M 18.05M 3.80M
Change to liabilities - - - 0.66M -0.27M
Total cashflows from investing activities -5.32M -10.30M - -3.20M -23.65M
Net borrowings -0.03M -0.01M - -0.01M 14.98M
Total cash from financing activities 10.50M 2.29M 1.95M 1.79M 20.45M
Change to operating activities - - - -1.93M 1.97M
Net income -15.70M -9.96M -21.72M -28.95M -26.98M
Change in cash 5.99M -3.47M 15.49M -17.47M -16.60M
Begin period cash flow 33.55M 37.03M 21.54M 39.01M 55.61M
End period cash flow 39.55M 33.55M 37.03M 21.54M 39.01M
Total cash from operating activities 0.81M 4.54M -5.72M -16.07M -13.40M
Issuance of capital stock - - - 0.00M 0.00M
Depreciation 8.19M 7.84M 5.55M 4.85M 4.74M
Other cashflows from investing activities -1.85M -10.30M - -1.18M 0.95M
Change to inventory -9.19M -10.16M -6.05M -3.66M -7.48M
Change to account receivables -2.46M 0.39M -2.69M -4.64M -0.50M
Sale purchase of stock - - - 1.81M 5.47M
Other cashflows from financing activities 10.50M 2.30M 1.96M 1.81M 5.47M
Change to netincome - - - 16.70M 14.29M
Capital expenditures 3.75M 4.52M 14.92M 21.25M 28.40M
Change receivables - - - -4.64M -0.50M
Cash flows other operating - - - -0.17M 3.79M
Cash and cash equivalents changes - - - -17.47M -16.60M
Change in working capital -24.62M -10.04M -4.39M -9.56M -6.28M
Stock based compensation 30.11M 15.91M 14.42M 15.59M 10.92M
Other non cash items 2.83M 0.80M 0.41M 2.00M 0.83M
Free cash flow -2.93M 0.01M -20.63M -37.32M -41.80M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AXGN
Axogen Inc
1.58
2.85%
56.95 - 142.86 8.27 15.00 8.70 3862.43
ABT
Abbott Laboratories
-
-%
104.48 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-1.43
1.40%
100.89 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-3.48
1.09%
314.67 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-0.10
0.22%
47.50 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Axogen Inc

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

13631 Progress Boulevard, Alachua, FL, United States, 32615

386 462 6800

622

Name Title Year Born
Ms. Karen Zaderej Chairman, Pres & CEO 1962
Mr. Peter J. Mariani Exec. VP & CFO 1964
Ms. Maria D. Martinez Chief HR Officer 1968
Mr. Angelo G. Scopelianos Ph.D. Chief R&D Officer 1955
Mr. Michael Donovan VP of Operations 1965
Ed Joyce Director of Investor Relations NA
Mr. Bradley L. Ottinger J.D. Gen. Counsel & Chief Compliance Officer 1970
Mr. Gregory Davault VP of Marketing 1968
Ms. Doris Quackenbush VP of Sales NA
Ms. Isabelle Billet Chief Strategy & Bus. Devel. Officer 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…